US Edition
Quantum signs agreement to prep FDA filing for Lucid-MS Phase 2 trial
Summary by Multiple Sclerosis News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Quantum signs agreement to prep FDA filing for Lucid-MS Phase 2 trial
Quantum Biopharma has signed an agreement with a global pharmaceutical contract research organization to continue advancing Lucid-21-302, its experimental therapy for promoting myelin repair with multiple sclerosis (MS). The collaboration […] The post Quantum inks agreement to prep filing for Lucid-MS Phase 2 trial appeared first on Multiple Sclerosis News Today.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage